International Journal of Cancer Research & Therapy(IJCRT)
ISSN: 2476-2377 | DOI: 10.33140/IJCRT
Impact Factor: 1.3
Guilherme A. Lepski
Hospital das Clínicas, Laboratory of Experimental Surgery (LIM26), Medical School, Universidade de São Paulo, São Paulo, Brazil
Publications
-
Research Article
Quality of Life Analysis In Patients Submitted to Dendritic Cell Vaccination for High Grade Gliomas Update Report on A Phase Ii Dc Trial
Author(s): Guilherme A. Lepski*, Nataly Peres, Zupo Crescencia, Patricia C. Bergami-Santos, Mariana P. Pinho, Nadia E. Chauca Torres, Gabriela C. M. Evangelista, Sarah F. Teixeira, Elizabeth Flatow, Jaqueline V. de Oliveira, Carla Fogolin, Analia Arevalo, Venancio A.F. Alves and Jose A. M. Barbuto
Measuring quality of life (QoL) in patients with high-grade central nervous system (CNS) malignancies is crucial, as these patients often endure severe physical, cognitive, and emotional challenges that significantly impact their overall well-being. Understanding and improving QoL is essential for guiding treatment strategies that not only extend survival but also enhance daily functioning and patient satisfaction. This manuscript details a phase II trial investigating the effects of allogeneic dendritic cell (DC) vaccination in patients with recurrent glioblastoma (IDH-1 wild type) and grade 4 astrocytoma (IDH-1 mutated). Among the 37 participants enrolled, comprehensive quality of life data were analyzed for 20 patients. The results revealed a significant survival benefit, with median survival extended by 75% in the vaccinated glioblastoma group and by 200% in the astrocytoma group,.. Read More»